Critical Contrast: ProPhase Labs (NASDAQ:PRPH) & Shineco (NASDAQ:SISI)

ProPhase Labs (NASDAQ:PRPH) and Shineco (NASDAQ:SISI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for ProPhase Labs and Shineco, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1	0	0	0	1.00
Shineco	1	0	0	0	1.00

Institutional & Insider Ownership

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 4.1% of Shineco shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by company insiders. Comparatively, 0.0% of Shineco shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ProPhase Labs and Shineco’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Shineco	-380.55%	-79.89%	-33.01%

Volatility and Risk

ProPhase Labs has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Shineco has a beta of -1.89, suggesting that its stock price is 289% less volatile than the S&P 500.

Earnings and Valuation

This table compares ProPhase Labs and Shineco”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.05 million	0.08	-$53.36 million	($3.90)	-0.02
Shineco	$9.60 million	0.00	-$22.45 million	($204.00)	-0.00

Shineco has higher revenue and earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Summary

Shineco beats ProPhase Labs on 6 of the 11 factors compared between the two stocks.

About ProPhase Labs

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

About Shineco

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.